Fund moves
4.6%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
EDSA · NASDAQ · Pharmaceutical Preparations
Edesa Biotech (EDSA) · oqro.io/stocks/EDSA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Edesa Biotech was filed in the last 90 days. The latest on record was on Mar 12, 2026.
Since 2018, Edesa Biotech insiders reported 46 open-market purchases and 16 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2026.
No open-market sale by an insider of Edesa Biotech (EDSA) was filed with the SEC in the last 90 days.
No trade in Edesa Biotech (EDSA) was disclosed by a member of Congress in the last 12 months.
Edesa Biotech's next results are expected on Dec 10, 2026, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.89−0.05 (−2.58%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
+8.9% (+$0.155) from Nov 17, 2025 to Nov 16, 2026 · adjusted daily closes
Adjusted close went from $1.74 on Nov 17, 2025 to $1.89 on Nov 16, 2026 (+8.9%). Disclosed in this range: 9 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Toronto.
Last 12 months
+8.3%
Market value
$18.2M
S&P 500 +10.1% over the same dates. Prices adjusted for splits and dividends.
Short interest: 158K shares sold short (1.6% of shares outstanding), −2.0% vs the previous count, 4.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $10.3M, at Jun 30, 2026
Net income, last 12 months
−$14.1M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 13, 2026.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last results
Aug 13, 2026
More than 30 days ago
Next results, expected
Dec 10, 2026
after the market closes; the date can move until the company confirms it
Purchases after results
59%
27 of 46 insider purchases since 2014 came within 30 days after a results announcement
From Edesa Biotech's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Edesa Biotech's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Insiders of Edesa Biotech reported 46 open-market purchases and 16 sales since 2018; purchases in 5 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $233K9×9 trades | — |
| 2024 | $20K1×1 trade | — |
| 2023 | — | $787K4×4 trades |
| 2022 | $135K19×19 trades | — |
| 2021 | $83K4×4 trades | $58K2×2 trades |
| 2020 | $537K13×13 trades | — |
| 2019 | — | $15K2×2 trades |
| 2018 | — | $42K8×8 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Sirenia Capital Management LP
Schedule 13G: passive · filed Nov 16, 2026 · 3.34M shares
StemPoint Capital LP
Schedule 13G: passive · filed Nov 16, 2026 · 1.41M shares
Millennium Management LLC
Schedule 13G: passive · filed Nov 4, 2026 · 1.18M shares
Adage Capital Management, L.P.
Schedule 13G: passive · filed Nov 12, 2026 · 1.1M shares
Boxer Capital Management, LLC
Schedule 13G: passive · filed Nov 16, 2026 · 937K shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in non-segmental vitiligo (nsv). The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
On the public record for Edesa Biotech over the 12 months to Nov 17, 2026: 1 clinical trial.